Radiation plus chemotherapy to preserve the bladder
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a shorter, more focused radiation plan given at the same time as chemotherapy can control muscle-invasive bladder cancer while keeping the bladder. You may be offered bladder-preserving treatment if your cancer stage and health conditions fit the study rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer confirmed under a microscope
- Your tumor has reached the muscle layer or deeper (T2 or higher) after surgery
- Your pelvic lymph nodes look clear on pelvic CT or MRI (no spread there)
- You want to keep your bladder (bladder-conserving treatment)
- You are age 20 or older and can do usual daily activities (ECOG 0–1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts to your body's changes during treatment. It aims to reduce side effects and improve accuracy for people with bladder cancer.
This trial tests whether adding radiation therapy to immunotherapy after bladder removal surgery can help prevent cancer from coming back. It's for people with advanced bladder cancer who have already started immunotherapy.
This trial tests whether radiation therapy (high-energy beams to kill cancer cells) can be a good treatment for bladder cancer that hasn't gone away after BCG therapy, offering an alternative to surgery to remove the bladder. It aims to see if this approach can control the cancer while possibly preserving your bladder.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests if a shorter course of radiation therapy works as well as the usual longer course for people with bladder cancer who are also receiving standard chemotherapy. The goal is to see if shorter treatment can reduce side effects while still being effective.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.